Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Jul 21, 2013; 19(27): 4344-4350
Published online Jul 21, 2013. doi: 10.3748/wjg.v19.i27.4344
Published online Jul 21, 2013. doi: 10.3748/wjg.v19.i27.4344
Figure 1 Results of literature search.
Figure 2 Adherence rates reported by the included studies on Crohn’s disease for infliximab and adalimumab.
The vertical axis rank-orders the therapeutic agents by the adherence rates and the horizontal axis by number of patients included. IFX: Infliximab; ADA: Adalimumab.
Figure 3 Adherence rates reported by the included studies on rheumatoid arthritis for infliximab, adalimumab and etanercept.
The vertical axis rank-orders the therapeutic agents by the adherence rates and the horizontal axis by number of patients included. IFX: Infliximab; ADA: Adalimumab; ETA: Etanercept.
- Citation: Fidder HH, Singendonk MM, van der Have M, Oldenburg B, van Oijen MG. Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn’s disease and rheumatoid arthritis: Results of a systematic review. World J Gastroenterol 2013; 19(27): 4344-4350
- URL: https://www.wjgnet.com/1007-9327/full/v19/i27/4344.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i27.4344